Amyotrophic Lateral Sclerosis

"Amyotrophic Lateral Sclerosis" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure, which enables searching at various levels of specificity.

MeSH information

Definition | Details | More General Concepts | Related Concepts | More Specific Concepts

A degenerative disorder affecting upper MOTOR NEURONS in the brain and lower motor neurons in the brain stem and SPINAL CORD. Disease onset is usually after the age of 50 and the process is usually fatal within 3 to 6 years. Clinical manifestations include progressive weakness, atrophy, FASCICULATION, hyperreflexia, DYSARTHRIA, dysphagia, and eventual paralysis of respiratory function. Pathologic features include the replacement of motor neurons with fibrous ASTROCYTES and atrophy of anterior SPINAL NERVE ROOTS and corticospinal tracts. (From Adams et al., Principles of Neurology, 6th ed, pp1089-94)

Descriptor ID	D000690
MeSH Number(s)	C10.228.854.139 C10.574.562.250 C10.574.950.050 C10.668.467.250 C18.452.845.800.050
Concept/Terms	Amyotrophic Lateral Sclerosis Amyotrophic Lateral Sclerosis Sclerosis, Amyotrophic Lateral Charcot Disease Motor Neuron Disease, Amyotrophic Lateral Sclerosis Lou Gehrig Disease Lou Gehrig's Disease Lou-Gehrigs Disease Disease, Lou-Gehrigs ALS (Amyotrophic Lateral Sclerosis) Gehrig's Disease Gehrig Disease Gehrigs Disease Amyotrophic Lateral Sclerosis, Guam Form Amyotrophic Lateral Sclerosis, Guam Form Amyotrophic Lateral Sclerosis, Parkinsonism-Dementia Complex of Guam Amyotrophic Lateral Sclerosis, Parkinsonism Dementia Complex of Guam Guam Form of Amyotrophic Lateral Sclerosis Amyotrophic Lateral Sclerosis-Parkinsonism-Dementia Complex 1 Amyotrophic Lateral Sclerosis Parkinsonism Dementia Complex 1 Guam Disease Disease, Guam Amyotrophic Lateral Sclerosis With Dementia Amyotrophic Lateral Sclerosis With Dementia Dementia With Amyotrophic Lateral Sclerosis

Below are MeSH descriptors whose meaning is more general than "Amyotrophic Lateral Sclerosis".

Diseases [C]
Nervous System Diseases [C10]
Central Nervous System Diseases [C10.228]
Spinal Cord Diseases [C10.228.854]
Amyotrophic Lateral Sclerosis [C10.228.854.139]
Neurodegenerative Diseases [C10.574]
Motor Neuron Disease [C10.574.562]
Amyotrophic Lateral Sclerosis [C10.574.562.250]
TDP-43 Proteinopathies [C10.574.950]
Amyotrophic Lateral Sclerosis [C10.574.950.050]
Neuromuscular Diseases [C10.668]
Motor Neuron Disease [C10.668.467]
Amyotrophic Lateral Sclerosis [C10.668.467.250]
Nutritional and Metabolic Diseases [C18]
Metabolic Diseases [C18.452]
Proteostasis Deficiencies [C18.452.845]
TDP-43 Proteinopathies [C18.452.845.800]
Amyotrophic Lateral Sclerosis [C18.452.845.800.050]

Below are MeSH descriptors whose meaning is more specific than "Amyotrophic Lateral Sclerosis".

publications

Timeline | Most Recent

This graph shows the total number of publications written about "Amyotrophic Lateral Sclerosis" by people in this website by year, and whether "Amyotrophic Lateral Sclerosis" was a major or minor topic of these publications.

Bar chart showing 207 publications over 29 distinct years, with a maximum of 16 publications in 2014

To see the data from this visualization as text, click here.

Year	Major Topic	Minor Topic	Total
1996	1	0	1
1998	2	0	2
1999	1	0	1
2000	2	0	2
2001	4	0	4
2002	3	0	3
2003	4	0	4
2004	3	0	3
2005	5	0	5
2006	9	1	10
2007	13	0	13
2008	11	0	11
2009	9	1	10
2010	10	1	11
2011	12	2	14
2012	12	0	12
2013	10	1	11
2014	12	4	16
2015	6	1	7
2016	8	2	10
2017	8	1	9
2018	7	3	10
2019	5	0	5
2020	4	1	5
2021	6	1	7
2022	7	0	7
2023	3	0	3
2024	6	1	7
2025	4	0	4

Below are the most recent publications written about "Amyotrophic Lateral Sclerosis" by people in Profiles.

Loher P, Londin E, Ilieva H, Pasinelli P, Rigoutsos I. Re-Analyses of Samples From Amyotrophic Lateral Sclerosis Patients and Controls Identify Many Novel Small RNAs With Diagnostic And Prognostic Potential. Mol Neurobiol. 2025 Jul; 62(7):8135-8149.

View in: PubMed
Paganoni S, Fournier CN, Macklin EA, Chibnik LB, Quintana M, Saville BR, Detry MA, Vestrucci M, Marion J, McGlothlin A, Ajroud-Driss S, Chase M, Pothier L, Harkey BA, Yu H, Sherman AV, Shefner JM, Hall M, Kittle G, Berry JD, Babu S, Andrews J, Dagostino D, Tustison E, Giacomelli E, Scirocco E, Alameda G, Locatelli E, Ho D, Quick A, Katz J, Heitzman D, Appel SH, Shroff S, Felice K, Maragakis NJ, Simmons Z, Miller TM, Olney N, Weiss MD, Goutman SA, Fernandes JA, Jawdat O, Owegi MA, Foster LA, Vu T, Ilieva H, Newman DS, Arcila-Londono X, Jackson CE, Ladha S, Heiman-Patterson T, Caress JB, Swenson A, Peltier A, Lewis R, Fee D, Elliott M, Bedlack R, Kasarskis EJ, Elman L, Rosenfeld J, Walk D, McIlduff C, Twydell P, Young E, Johnson K, Rezania K, Goyal NA, Cohen JA, Benatar M, Jones V, Glass J, Shah J, Beydoun SR, Wymer JP, Zilliox L, Nayar S, Pattee GL, Martinez-Thompson J, Harvey B, Patel S, Mahoney P, Duda PW, Cudkowicz ME. Efficacy and Safety of Zilucoplan in Amyotrophic Lateral Sclerosis: A Randomized Clinical Trial. JAMA Netw Open. 2025 02 03; 8(2):e2459058.

View in: PubMed
Hollin IL, Giler G, Heiman-Patterson TD. Health Care Delivery and Financial Considerations in Amyotrophic Lateral Sclerosis Clinics: A Survey of Clinic Directors. Neurology. 2025 02 25; 104(4):e210015.

View in: PubMed
Kim KM, Girdhar A, Cicardi ME, Kankate V, Hayashi M, Yang R, Carey JL, Fare CM, Shorter J, Cingolani G, Trotti D, Guo L. NLS-binding deficient Kap?2 reduces neurotoxicity via selective interaction with C9orf72-ALS/FTD dipeptide repeats. Commun Biol. 2025 Jan 02; 8(1):2.

View in: PubMed
Ko YH, Lokareddy RK, Doll SG, Yeggoni DP, Girdhar A, Mawn I, Klim JR, Rizvi NF, Meyers R, Gillilan RE, Guo L, Cingolani G. Single Acetylation-mimetic Mutation in TDP-43 Nuclear Localization Signal Disrupts Importin a1/? Signaling. J Mol Biol. 2024 Oct 15; 436(20):168751.

View in: PubMed
Nelson AT, Cicardi ME, Markandaiah SS, Han JY, Philp NJ, Welebob E, Haeusler AR, Pasinelli P, Manfredi G, Kawamata H, Trotti D. Glucose hypometabolism prompts RAN translation and exacerbates C9orf72-related ALS/FTD phenotypes. EMBO Rep. 2024 May; 25(5):2479-2510.

View in: PubMed
Arag?n-Gonz?lez A, Shaw AC, Kok JR, Roussel FS, Santos Souza CD, Granger SM, Vetter T, de Diego Y, Meyer KC, Beal SN, Shaw PJ, Ferraiuolo L. C9ORF72 patient-derived endothelial cells drive blood-brain barrier disruption and contribute to neurotoxicity. Fluids Barriers CNS. 2024 Apr 11; 21(1):34.

View in: PubMed
Cicardi ME, Kankate V, Sriramoji S, Krishnamurthy K, Markandaiah SS, Verdone BM, Girdhar A, Nelson A, Rivas LB, Boehringer A, Haeusler AR, Pasinelli P, Guo L, Trotti D. The nuclear import receptor Kap?2 modifies neurotoxicity mediated by poly(GR) in C9orf72-linked ALS/FTD. Commun Biol. 2024 03 28; 7(1):376.

View in: PubMed
Cheslow L, Snook AE, Waldman SA. Biomarkers for Managing Neurodegenerative Diseases. Biomolecules. 2024 Mar 26; 14(4).

View in: PubMed
Urban MW, Charsar BA, Heinsinger NM, Markandaiah SS, Sprimont L, Zhou W, Brown EV, Henderson NT, Thomas SJ, Ghosh B, Cain RE, Trotti D, Pasinelli P, Wright MC, Dalva MB, Lepore AC. EphrinB2 knockdown in cervical spinal cord preserves diaphragm innervation in a mutant SOD1 mouse model of ALS. Elife. 2024 Jan 15; 12.

View in: PubMed

People

Explore

Similar Concepts

Top Journals

The Thomas Jefferson University web site, its contents and programs, is provided for informational and educational purposes only and is not intended as medical advice nor is it intended to create any physician-patient relationship. Please remember that this information should not substitute for a visit or a consultation with a health care provider. The views or opinions expressed in the resources provided do not necessarily reflect those of Thomas Jefferson University, Thomas Jefferson University Hospital, or the Jefferson Health System or staff.
Please read our Privacy Statement